Accéder au contenu
Merck

Genetically engineered FGF1-sericin hydrogel material treats intrauterine adhesion and restores fertility in rat.

Regenerative biomaterials (2022-04-29)
Chun-Yi Guan, Feng Wang, Lu Zhang, Xue-Cheng Sun, Dan Zhang, Hu Wang, Hong-Fei Xia, Qing-You Xia, Xu Ma
RÉSUMÉ

Endometrial injury can cause intrauterine adhesions (IUA) and induce the formation of endometrial fibrosis, leading to infertility and miscarriage. At present, there is no effective treatment method for severe IUA and uterine basal injury with adhesion area larger than one-third of the uterus. In this study, we prepared FGF1 silk sericin hydrogel material (FGF1-SS hydrogel) to treat endometrial injury and prevent endometrial fibrosis. Compared with the silk sericin hydrogel material (WT-SS hydrogel), FGF1-SS hydrogel significantly promotes the cell migration and infiltration ability of endometrial stromal cells (ESCs). More importantly, FGF1-SS hydrogel can release FGF1 stably for a long time and inhibit the ESCs injury model forms fibrosis through the TGF-β/Smad pathway. In the IUA rat model, FGF1-SS hydrogel treatment effectively restored the number of uterine glands and uterine wall thickness in rats, with a fertility rate of 65.1% ± 6.4%. The results show that FGF1-SS hydrogel is expected to be a candidate to prevent IUA.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Monoclonal Anti-Vimentin antibody produced in mouse, clone V9, ascites fluid